Wells Fargo Rates Hinge Health (HNGE) buy, $90 Price Target
Wells Fargo analyst Stan Berenshteyn keeps a buy rating on Hinge Health as the healthcare tech firm draws widespread attention from Wall Street, a 19.78% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Wells Fargo rated Hinge Health, Inc. ($HNGE) "buy" with a $90 price target on June 24, 2026.
Since the rating, $HNGE is up 20.6% after 1 week, up 5.3% after 1 month and up 40.5% to date (from the $70.56 close on Jun 24, 2026).
HNGE
Hinge Health, Inc.
Key Points
- Wells Fargo analyst Stan Berenshteyn reiterated a buy rating on Hinge Health Inc. with a $90.00 price target on June 24, 2026.
- Wells Fargo's $90 price target implies 19.78% upside from Hinge Health, Inc.'s ($HNGE) current $75.14 share price.
- Hinge Health shares trade near $75.14, supported by strong revenue growth and a market value of about $8.47 billion.
- Multiple firms including Keybanc, Barclays, and Stifel have recently updated their price targets on the healthcare technology provider.
Get $HNGE trade alerts by text
We text you when insiders, Congress or big funds trade $HNGE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Hinge Health, Inc. alert may contain errors. Disclosures
Wells Fargo Keeps Buy Rating on Hinge Health
Wells Fargo analyst Stan Berenshteyn reiterated a buy rating on Hinge Health, Inc. (NYSE: HNGE) on June 24, 2026, keeping a $90.00 price target on the shares. The call highlights confidence in the healthcare technology firm as it builds out its digital care platforms for self-insured employers. Shares recently changed hands at $75.14, reflecting active interest from major financial institutions tracking the digital health space.
Wells Fargo vs. the S&P 500
Hypothetical returns from Wells Fargo's disclosed trades, not real profit or advice. How we model this.
Wall Street Analyst Updates and Price Targets
Other major financial institutions have adjusted their views on Hinge Health in recent months. Keybanc maintained an overweight rating on October 16, 2026, and lifted its target to $140.00 from $125.00. Barclays kept an overweight rating on October 12, 2026, raising its target to $110.00 from $100.00. Needham maintained a buy rating on September 30, 2026, moving its target to $115.00 from $97.00, while Baird kept a neutral rating on September 22, 2026, with a target of $90.00 up from $85.00. Stifel maintained a buy rating on September 8, 2026, lifting its target to $115.00 from $96.00. Truist Securities maintained a buy rating on August 11, 2026, with a target of $112.00 up from $85.00, and RBC Capital kept an outperform rating on August 5, 2026, raising its target to $110.00 from $75.00. Citizens maintained a market outperform rating on the same day with a target of $107.00.
Hinge Health Stock Performance and Valuation
The company trades with a market capitalization of roughly $8.47 billion. The stock sits between its 52-week low of $30.08 and a high of $107.00, staying well above its lower bounds as analysts review its fundamentals.
$HNGE price target
Hinge Health, Inc. daily closes and this analyst's $90 target. Not advice.
Recent Earnings and Financial Health
Hinge Health reported $720.06 million in revenue with revenue growth of 0.53%. The firm posted an earnings per share of $3.03, alongside a net margin of 15.15% and a return on equity of 30.38%. Investors will look toward the company's next earnings report scheduled for November 2, 2026, to gauge ongoing revenue growth and profitability metrics.
Inside Hinge Health Operations
Based in San Francisco, California, Hinge Health builds technology designed to scale and automate care delivery for musculoskeletal system conditions. The company relies on AI-powered motion tracking and wearable devices to serve self-insured employers managing chronic pain and post-surgical care. Founded in 2012, the firm employs over 1,400 people to expand its digital health offerings.
What to Watch at Hinge Health, Inc.
Market participants will monitor upcoming analyst updates and the upcoming November earnings release for further signals on operational performance. These evaluations remain subject to changing market conditions and future corporate disclosures.
Related Filing Alerts
Source: Wells Fargo's rating change on $HNGE (Jun 24, 2026). Written by software, not financial advice. How we make alerts